DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers
Key Highlights
- ➤Humana Medicaid policy covers ChemoFx for specified gynecologic cancer indications
- ➤ChemoFx is billed under CPT codes 81535 and 81536
- ➤ChemoFx showed $6,206 incremental cost per life-year saved in recurrent ovarian cancer
- ➤Assay-assisted treatment costs averaged $33,187 versus $48,758 for empiric treatment
- ➤Helomics plans additional ChemoFx data publications supporting potential label expansion
Expert Statements
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“We are very pleased that Humana has included the ChemoFx Assay in its Medicaid coverage policy for gynecologic cancers”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“ChemoFx gives oncologists patient-specific information on how a tumor responds to a range of chemotherapy agents, supported by peer-reviewed clinical utility data on treatment outcomes based on ChemoFx-enabled therapeutic selection in gynecologic cancers.”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“The evidence for ChemoFx in gynecologic cancers was reviewed in the 2021 gynecologic cancer peer-reviewed publication on ChemoFx, as well as the 2015 cost savings peer-reviewed publication in epithelial ovarian cancer (EOC) (link).”
Gerald E. Commissiong, Interim Co-CEO of DataMEDS
“We believe there is an opportunity to evaluate ChemoFx in additional settings, including difficult-to-treat cancers, and we are preparing data for publication to support label expansion.”
TAMPA, FL / ACCESS Newswire / October 12, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company vertically integrating its Health IT and physical infrastructure together with its super intelligence platform EinsteinRx(™) and smart contracts platform PharmacyChain(™), today announced that its recently acquired CLIA-certified precision oncology laboratory subsidiary Helomics Corporation has received a Medicaid coverage determination in gynecologic cancers for the ChemoFx(®) Assay, a commercially available chemoresponse test that measures how a patient's live tumor cells respond to chemotherapy agents, in gynecologic cancers. Medical Coverage Policies were reviewed by Humana's Medicaid Coverage Policy Adoption (MCPA) Forum, which incorporated the ChemoFx Assay in its Coverage Determination for Pharmacogenomics Testing([1]).
Get started
Create a free account to read the full story.